Press releases

* (R) = Regulatory press releases

May 21, 2018

(R) Cantargia receives Notice of Allowance from USPTO for the antibody CAN03
May 16, 2018

(R) Cantargia’s immuno-oncology project CAN04 shows promise in additional cancer forms
May 15, 2018

(R) Cantargia publishes interim report for first quarter 2018
May 4, 2018

(R) Cantargia’s European patents for both leukemia and solid tumours remain valid after appeal period ends
May 3, 2018

(R) Cantargia receives patent approval in Canada and broadens protection with respect to hematological cancer
Apr 16, 2018

(R) Cantargia presents anti-metastatic effect of IL1RAP blocking antibody at AACR
Mar 15, 2018

(R) Cantargia presents new data at AACR on inhibition of metastasis by antibodies against IL1RAP.
Mar 6, 2018

(R) Cantargia: antibody against ILRAP reduce metastases in experimental cancer model.
Feb 28, 2018

(R) Cantargia publishes year end report for 2017
Feb 27, 2018

(R) Cantargia receives Notice of Allowance from USPTO for expanded protection in treatment of leukemia
<< Newer press releases    Older press releases >>

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB